Document Detail


Experience with paclitaxel-eluting Infinnium coronary stents.
MedLine Citation:
PMID:  18984753     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To investigate the safety and efficacy of the Infinnium Paclitaxel-eluting stents in the treatment of coronary artery lesions, 196 patients with symptomatic coronary disease who received 202 stents at our center from January 2004 to November 2005 were studied prospectively. The primary study endpoint was the incidence of abnormalities on exercise electrocardiograms or cardiac single-photon emission tomography at 6 months, as a noninvasive index of stent reocclusion. Secondary endpoints were the rates of major adverse cardiac events at 1, 3, 6, 9, and 12 months. Stent deployment was successful in 98% of patients. Cumulative major adverse cardiac event rates at the end of 12 months were: cardiac death 1%, myocardial infarction 5% (Q-wave 2.5%, non-Q-wave 2.5%), and repeat revascularization of the stented lesion 3%. The overall major adverse cardiac event rate was 8.1%. There were 6 (3%) stent thromboses; all occurred late after the procedure. In patients with symptomatic ischemic heart disease, the low-cost Infinnium stent proved both effective and safe, with an acceptably low major adverse cardiac event rate.
Authors:
Mohammad A Ostovan; Reza Mollazadeh; Javad Kojuri; Mohammad Mirabadi
Related Documents :
10604223 - Self-expandable metallic stents in malignant gastric outlet obstructions--an alternativ...
17052303 - Comparison of natural and dumon airway stents for the management of benign tracheobronc...
11902093 - Treatment paradigms in heart failure.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Asian cardiovascular & thoracic annals     Volume:  16     ISSN:  1816-5370     ISO Abbreviation:  Asian Cardiovasc Thorac Ann     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2008-11-05     Completed Date:  2009-01-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9503417     Medline TA:  Asian Cardiovasc Thorac Ann     Country:  Singapore    
Other Details:
Languages:  eng     Pagination:  454-8     Citation Subset:  IM    
Affiliation:
Cardiology Department, Nemazee Hospital, Shiraz, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Transluminal, Percutaneous Coronary / adverse effects,  instrumentation*,  mortality
Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography
Cardiovascular Agents / administration & dosage*
Cardiovascular Diseases / diagnosis,  etiology*,  mortality
Coronary Stenosis / mortality,  therapy*
Drug-Eluting Stents*
Electrocardiography
Exercise Test
Female
Humans
Kaplan-Meiers Estimate
Male
Middle Aged
Paclitaxel / administration & dosage*
Prospective Studies
Prosthesis Design
Registries
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Cardiovascular Agents; 33069-62-4/Paclitaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fibrin glue administration to support bronchial stump line.
Next Document:  Minimally invasive thoracoscope-assisted Heller myotomy for achalasia.